Siglec-15 Antibody (Medimmune patent anti-Siglec-15) [mFluor Violet 500 SE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28018MFV500
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
mFluor Violet 500 SE (Excitation = 410 nm, Emission = 501 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Medimmune patent anti-Siglec-15
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Siglec-15 / CD33L3
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Siglec-15
Long Name
Sialic Acid Binding Ig-like Lectin 15
Alternate Names
CD33L3, HsT1361, Siglec15
Gene Symbol
SIGLEC15
Additional Siglec-15 Products
Product Specific Notices
mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...